Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

What Is the Role of Imaging at Primary Diagnostic Work-Up in Uterine Cervical Cancer?

IS. Haldorsen, N. Lura, J. Blaakær, D. Fischerova, HMJ. Werner,

. 2019 ; 21 (9) : 77. [pub] 20190729

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

E-resources Online Full text

NLK ProQuest Central from 2013-01-01 to 1 year ago
Medline Complete (EBSCOhost) from 1999-01-01 to 1 year ago
Health & Medicine (ProQuest) from 2013-01-01 to 1 year ago

PURPOSE OF REVIEW: For uterine cervical cancer, the recently revised International Federation of Gynecology and Obstetrics (FIGO) staging system (2018) incorporates imaging and pathology assessments in its staging. In this review we summarize the reported staging performances of conventional and novel imaging methods and provide an overview of promising novel imaging methods relevant for cervical cancer patient care. RECENT FINDINGS: Diagnostic imaging during the primary diagnostic work-up is recommended to better assess tumor extent and metastatic disease and is now reflected in the 2018 FIGO stages 3C1 and 3C2 (positive pelvic and/or paraaortic lymph nodes). For pretreatment local staging, imaging by transvaginal or transrectal ultrasound (TVS, TRS) and/or magnetic resonance imaging (MRI) is instrumental to define pelvic tumor extent, including a more accurate assessment of tumor size, stromal invasion depth, and parametrial invasion. In locally advanced cervical cancer, positron emission tomography-computed tomography (PET-CT) or computed tomography (CT) is recommended, since the identification of metastatic lymph nodes and distant metastases has therapeutic consequences. Furthermore, novel imaging techniques offer visualization of microstructural and functional tumor characteristics, reportedly linked to clinical phenotype, thus with a potential for further improving risk stratification and individualization of treatment. Diagnostic imaging by MRI/TVS/TRS and PET-CT/CT is instrumental for pretreatment staging in uterine cervical cancer and guides optimal treatment strategy. Novel imaging techniques may also provide functional biomarkers with potential relevance for developing more targeted treatment strategies in cervical cancer.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025762
003      
CZ-PrNML
005      
20201222155413.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s11912-019-0824-0 $2 doi
035    __
$a (PubMed)31359169
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Haldorsen, Ingfrid S $u Mohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, Jonas Liesvei 65, Postbox 7800, 5021, Bergen, Norway. ingfrid.haldorsen@helse-bergen.no. Section for Radiology, Department of Clinical Medicine, University of Bergen, 5020, Bergen, Norway. ingfrid.haldorsen@helse-bergen.no.
245    10
$a What Is the Role of Imaging at Primary Diagnostic Work-Up in Uterine Cervical Cancer? / $c IS. Haldorsen, N. Lura, J. Blaakær, D. Fischerova, HMJ. Werner,
520    9_
$a PURPOSE OF REVIEW: For uterine cervical cancer, the recently revised International Federation of Gynecology and Obstetrics (FIGO) staging system (2018) incorporates imaging and pathology assessments in its staging. In this review we summarize the reported staging performances of conventional and novel imaging methods and provide an overview of promising novel imaging methods relevant for cervical cancer patient care. RECENT FINDINGS: Diagnostic imaging during the primary diagnostic work-up is recommended to better assess tumor extent and metastatic disease and is now reflected in the 2018 FIGO stages 3C1 and 3C2 (positive pelvic and/or paraaortic lymph nodes). For pretreatment local staging, imaging by transvaginal or transrectal ultrasound (TVS, TRS) and/or magnetic resonance imaging (MRI) is instrumental to define pelvic tumor extent, including a more accurate assessment of tumor size, stromal invasion depth, and parametrial invasion. In locally advanced cervical cancer, positron emission tomography-computed tomography (PET-CT) or computed tomography (CT) is recommended, since the identification of metastatic lymph nodes and distant metastases has therapeutic consequences. Furthermore, novel imaging techniques offer visualization of microstructural and functional tumor characteristics, reportedly linked to clinical phenotype, thus with a potential for further improving risk stratification and individualization of treatment. Diagnostic imaging by MRI/TVS/TRS and PET-CT/CT is instrumental for pretreatment staging in uterine cervical cancer and guides optimal treatment strategy. Novel imaging techniques may also provide functional biomarkers with potential relevance for developing more targeted treatment strategies in cervical cancer.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lymfatické metastázy $7 D008207
650    _2
$a magnetická rezonanční tomografie $x metody $7 D008279
650    _2
$a staging nádorů $7 D009367
650    _2
$a PET/CT $x metody $7 D000072078
650    _2
$a počítačová rentgenová tomografie $x metody $7 D014057
650    _2
$a ultrasonografie $x metody $7 D014463
650    _2
$a nádory děložního čípku $x diagnostické zobrazování $x patologie $x terapie $7 D002583
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Lura, Njål $u Mohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, Jonas Liesvei 65, Postbox 7800, 5021, Bergen, Norway.
700    1_
$a Blaakær, Jan $u Department of Obstetrics and Gynaecology, Odense University Hospital, Odense, Denmark.
700    1_
$a Fischerova, Daniela $u Gynecological Oncology Centre, Department of Obstetrics and Gynaecology, First Faculty of Medicine, Charles University, General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Werner, Henrica M J $u Department of Obstetrics and Gynaecology, Maastricht University Medical Centre, Maastricht, The Netherlands. Department of Clinical Science, University of Bergen, 5020, Bergen, Norway.
773    0_
$w MED00188750 $t Current oncology reports $x 1534-6269 $g Roč. 21, č. 9 (2019), s. 77
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31359169 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222155409 $b ABA008
999    __
$a ok $b bmc $g 1599907 $s 1116448
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 21 $c 9 $d 77 $e 20190729 $i 1534-6269 $m Current oncology reports $n Curr Oncol Rep $x MED00188750
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...